Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 632-639

  Cancello, G ^a   Maisonneuve, P ^b   Rotmensz, N ^b   Viale, G ^a,c   Mastropasqua, M G ^a   Pruneri, G ^a   Montagna, E ^a   Iorfida, I ^a   Mazza, M ^a   Balduzzi, A ^a   Veronesi, P ^a,c   Luini, A ^a   Intra, M ^a   Goldhirsch, A ^a   Colleoni, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Div of Epidemiol and Biostatistics   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; HER2; Immunohistochemistry; Luminal; Progesterone; Prognosis.

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; KI 67 ANTIGEN POSITIVE BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; RECURRENCE RISK; BREAST TUMOR; KAPLAN MEIER METHOD; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

MLCS; MLOWN;

EID: 84874565337     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds430     Document Type: Article

References (24)

1. Sorlie T, Tibshirani R, Parker J et al.. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
2. Oh DS, Troester MA, Usary J et al.. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol. 2006; 24: 1656-1664.
3. Rouzier R, Perou CM, Symmans WF et al.. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
4. Perou CM, Sorlie T, Eisen MB et al.. Molecular portraits of human breast tumors. Nature 2000; 406: 747-752.
5. Sorlie T, Perou CM, Tibshirani R et al.. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
6. Cheang MC, Chia SK, Voduc D et al.. Ki67 Index, HER2 Status, and prognosis ofz patients with luminal B breast Cancer. J Natl Cancer Inst 2009; 101: 736-750.
7. Cuzick J, Dowsett M, Pineda S et al.. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011; 29: 4273-4278.
8. Hugh J, Hanson J, Cheang MC et al.. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an Immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol 2009; 27: 1168-1176.
9. Goldhirsch A, Wood WC, Coates AS et al.. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011; 22: 1736-1747.
10. Marcom PK, Isaacs C, Harris L et al.. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007; 102: 43-49.
11. Bardou VJ, Arpino G, Elledge RM et al.. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003; 21: 1973-1979.
12. Cui X, Schiff R, Arpino G et al.. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23: 7721-7735.
13. Rakha EA, El-Sayed ME, Green AR et al.. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007; 25: 4772-4778.
14. Creighton CJ, Kent Osborne C, van de Vijver MJ et al.. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009; 114: 287-299.
15. Rosen PP, Oberman H. Tumors of the Mammary Gland. Washington, DC: Armed Forces Institute of Pathology 1993.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 1991; 19: 403-410.
17. Viale G, Regan MM, Mastropasqua MG et al.. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008; 100: 207-212.
18. Osborne CK, Shou J, Massarweh S et al.. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11: 865s-870s.
19. Arpino G, Weiss H, Lee AV et al.. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97: 1254-1261.
20. Taucher S, Rudas M, Mader RM et al.. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer 2003; 98: 2547-2553.
21. Huang HJ, Neven P, Drijkoningen M et al.. Association between tumor characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005; 58: 611-616.
22. Viale G, Regan MM, Maiorano E et al.. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25: 3846-3852.
23. Dowsett M, Allred C, Knox J et al.. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008; 26: 1059-1065.
24. Untch M, Gelber RD, Jackisch C et al.. HERA study team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19: 1090-1096.